NURLF (Neural Therapeutics) Cash Flow from Investing: $0.00 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Cash Flow from Investing?

Neural Therapeutics NURLF Cash Flow from Investing is $0.00 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jan. 2026, Neural Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Neural Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jan. 2026.


Neural Therapeutics  (OTCPK:NURLF) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Neural Therapeutics's purchase of property, plant, equipment for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Neural Therapeutics's sale of property, plant, equipment for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Neural Therapeutics's purchase of business for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Neural Therapeutics's sale of business for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Neural Therapeutics's purchase of investment for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Neural Therapeutics's sale of investment for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Neural Therapeutics's net Intangibles purchase and sale for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Neural Therapeutics's cash from discontinued investing activities for the three months ended in Jan. 2026 was 0.00 Mil. It means Neural Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Neural Therapeutics's cash from other investing activities for the three months ended in Jan. 2026 was $0.00 Mil. It means Neural Therapeutics paid $0.00 Mil for other investing activities.


Neural Therapeutics Cash Flow from Investing Related Terms


Neural Therapeutics Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Cash Flow from Investing Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cash Flow from Investing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neural Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Neural Therapeutics's Cash Flow from Investing for the fiscal year that ended in Jul. 2025 is calculated as:

Neural Therapeutics's Cash Flow from Investing for the quarter that ended in Jan. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of $0.00 Mil mean?
Neural Therapeutics (NURLF) has a Cash Flow from Investing of $0.00 Mil as of Jan. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Neural Therapeutics and its competitors.
Is Neural Therapeutics' Cash Flow from Investing too high?
Neural Therapeutics' current Cash Flow from Investing is $0.00 Mil.
How does Neural Therapeutics' Cash Flow from Investing compare to VRTX and REGN?
Neural Therapeutics' Cash Flow from Investing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Neural Therapeutics and its competitors. Neural Therapeutics's current Cash Flow from Investing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Cash Flow from Investing of $0.00 Mil. The current Cash Flow from Investing is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Cash Flow from Investing is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.